FDA
-
-
-
-
-
-
-
Baird Starts GRAIL, Inc. (GRAL) at Outperform
-
-
-
-
-
-
-
GRAIL study shows cancer test positive predictive value rises to 84.2%
-
-
-
-
-
-
-
GRAIL to Present New GalleriĀ® Data From More Than 32,000 Participants Across the PATHFINDER 2, SYMPLIFY and REFLECTION Studies at ESMO Congress 2025 and EDCC
-
-
-
-
-
-
-
GRAIL and athenahealth Team Up to Offer Healthcare Providers Streamlined Ordering of GRAIL's GalleriĀ® Multi-Cancer Early Detection (MCED) Test
-
-
-
-
-
-
-
GRAIL Announces First Patient Tested With Blood-Based Assay in Global Phase 3 Adjuvant Lung Cancer Study
-
-
-
-
-
-
-
GRAIL Advances the GalleriĀ® Registrational Clinical Trial Program
-
-
-
312,667 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

